CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 67 enrolled
Drug / intervention
DHA +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01007110
NCT01007110Phase 3Completed
CompareCT.gov

The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes

University of Kansas·interventional·Posted Nov 3, 2009·Updated Jun 9, 2014

In Brief

A Phase 3 clinical trial evaluating DHA and Placebo for Pregnancy. Completed, enrolled 67 participants across 1 site.

Detailed Summary

DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate and blood pressure and increasing heart variability. Little is known about how fatty acids impact cardiac control in infants, children or the fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR and increase fetal HRV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPregnancy
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 3, 2009
Enrollment StartMay 1, 2009
Primary CompletionMay 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.7 years ago

Interventions

DHAdietary

Docosahexaenoic Acid (DHA) from algal oil

Placeboother

Placebo capsule